Caris Life Sciences

How can AI help confirm rare cancer diagnoses? Caris GPSai combines machine learning with WES and WTS data to identify tumor origin. In a recent study, Caris GPSai helped diagnose an uncommon primary lung presentation of granulosa cell tumor, a typically ovarian cancer. Learn more: https://lnkd.in/g3rwMs_H

Join Caris at the USCAP - United States and Canadian Academy of Pathology Annual Meeting in Boston, MA. Visit our team at?booth 928?to discover the latest innovations in precision medicine and how our products and services are leading the molecular revolution. Learn more: https://lnkd.in/g27rWsjf

Caris Life Sciences has published a 295,000+ patient study revealing variable efficacy among cancers for patients treated with tissue-agnostic drugs and uncovering the potential for expanding approvals to other drugs in the same class.? ? “By harnessing the power of Caris’ large clinico-genomic dataset, we have shown that tissue-agnostic drugs produce different outcomes in different tissues,” said?George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris and study author. ? Our advanced analyses of real-world data now enable us to uncover findings of clinical value for large patient populations. One in five patients in our study were eligible for a tissue-agnostic drug, which demonstrates the widespread impact of our findings,” said Caris President and study author?David Spetzler, MS, PhD, MBA. ? Learn more:?https://lnkd.in/gcD8WZCj

Join Caris scientific and medical leaders as they discuss MI Cancer Seek, the first and only simultaneous WES/WTS-based assay with CDx indications for adult and pediatric patients (ages 1-22). Presenters will review cases that highlight the strengths of MI Cancer Seek in a clinical workflow. Register Now: https://lnkd.in/dMm7Nqmt Presenters: David Spetzler, MS, MBA, PhD Matthew Oberley, MD, PhD

How can whole transcriptome sequencing uncover potential prognostic biomarkers for patients with cancer? Our poster, presented by Tanvi Joshi, M.D., reports how tumor RNA sequencing revealed that high GPR171 expression is associated with improved survival in cervical cancer. https://lnkd.in/gPfKVsKS

Does it matter which IHC scoring system is used to evaluate HER2 in endometrial carcinoma? Visit Rachel Furuya, M.D.’s poster to discover how gastric and breast criteria perform in endometrial epithelial adenocarcinoma and the potential clinical implications of these results. https://lnkd.in/gPfKVsKS

What can 21,500+ ovarian and endometrial tumors tell us about the impact of CCNE1 amplification on patient outcomes? Discover the key findings from our large-scale study of molecular profiling and outcomes data at Erin George, M.D.’s oral presentation. https://lnkd.in/gPfKVsKS

What difference does molecular testing make for patients with low-grade serous ovarian carcinoma? Join Sydney Oesch, M.D.’s oral presentation to discover how molecular profiling can enhance treatment outcomes for this type of cancer and why specific MAPK mutations are key. https://lnkd.in/gPfKVsKS

Connect with Caris Life Sciences during the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Our experts are ready to chat at Booth 416 about our latest research, current product offerings, and what we have in store for the future of precision medicine. https://lnkd.in/ghckah5d

Is there a better way to classify ER status in endometrial cancer cases with ‘no specific molecular profile’ (NSMP)? Our analysis of the largest known dataset of these tumors suggests that implementing a three-tier ER classification system could enhance patient management. Learn more at Alexander Cohen, M.D.’s oral featured poster. https://lnkd.in/gPfKVsKS